Deniz Publication
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513


Publisher: Deniz Publication
ARTICLE
Year: 2021   |   Volume: 10   |   Issue: 4   |   Page: 153-181     View issue
Prognostic biomarkers for salivary adenoid cystic carcinoma: A systematic review
Aanchal Adwani, Supriya Kheur, Mohit Kheur, Pratiksha Mahajan

Background: Salivary Adenoid Cystic Carcinoma (ADCC), also known as “Wolf in Sheep's clothing,” is associated with poor prognosis. Regardless of the vigorous treatment, ADCC has been known to recur and metastasize. Hence, identifying informative prognostic biomarkers for Salivary ADCC is of great importance to better predict tumor behavior and to guide treatment planning. Various immunohistochemical biomarkers along with other factors like the histologic grade of the tumor, site of tumor, and age have been studied to establish their correlation with the prognosis of ADCC. Aim: The aim of the systematic review was to identify various markers that have the potential to predict the prognosis in salivary ADCC. Materials and Methods: A literature search was conducted using PubMed and Scopus as database and Google Scholar as an additional source. Studies that performed immunohistochemical analysis predicting the overall survival of patients with salivary ADCC were included in this review. Studies published from 1977 to August 2018 were included. Case reports, review, letter to editors, and articles in languages other than English were excluded from the review. The following outcomes were examined: overall/disease-free survival, metastasis, and recurrence using immunohistochemistry as a prognostic marker. Results: A number of biomarkers were identified by the evaluation of 68 studies, which predicted overall survival and prognosis in terms of recurrence and metastasis. Out of these biomarkers, four markers most frequently assessed markers were Ki-67, p53, vascular endothelial growth factor (VEGF), and cyclin D1, which showed reproducible results. Many other markers showed significant results, but since only a single study was carried out with these markers, it was difficult to assess their predictability. Conclusion: The review thus identified that Ki-67, p53, VEGF could effectively predict metastasis and recurrence in salivary ADCC. More research work is, however, required to validate the accuracy of these markers for their prognostic significance. Many other markers also showed a significant correlation to prognosis; however, multiple studies are required to establish their prognostic value.

Prognosis, salivary adenoid cystic carcinoma, tumor markers

Introduction

Adenoid cystic carcinoma (ADCC) is a relatively uncommon salivary gland neoplasm and accounts for 10% of all salivary gland tumors having a predisposition for minor salivary glands.[1] Among the major salivary glands, parotid gland ADCC accounts for 2%–3% of all tumors.[2] Although ADCC appears innocuous due to its slow growth and size, it has an invasive potential.[3] The clinical course of ADCC is aggressive and has a predisposition to distant metastasis and recurrence after the removal of the primary tumor. The most common site of distant metastasis of ADCC is the lungs.[2] This tumor also has a tendency for perineural invasion.[3]

Histologically, ADCC shows ductal and myoepithelial cell differentiation and is also known as “cylindroma” due to its histologic appearance. Three patterns of ADCC have been recognized: solid, tubular, and cribriform. The cribriform type shows a typical Swiss cheese pattern due to the cyst-like spaces within the tumor. The solid pattern is found to be associated with poor outcome.[3]

Complete surgical resection followed by radiotherapy remains the treatment of choice for ADCC. However, recurrence and distant metastasis still prevail. The median survival duration following disease metastasis is about 3 years.[4] Hence, it becomes necessary to identify the various factors that predict the prognosis of the tumor and improve the survival outcome. Although factors such as histologic grade, age, site and size of the primary tumor and positive resection margins have been suggested to have an impact on the survival and prognosis of the tumor, their role has not been clearly established.[3] Hence, it becomes essential to recognize biomarkers that could predict the prognosis in terms of metastasis and recurrence.

Various immunohistochemical markers have also been studied that speculate the progressive nature of ADCC. Immunohistochemistry is often used to establish the diagnosis of ADCC. Expression of biomarkers like p53 and Ki-67 have been associated with poor prognosis of the disease. Few markers like bcl-2 have also been predicted to have a role in the pathogenesis of ADCC. However, the prognostic specificity of such markers remains unexplored.[3]

The aim of this systematic review was to compile the data that shows the expression of various immunohistochemical markers and its correlation with recurrence/metastasis along with the overall survival of the patients, thereby aiding the surgeon to render effective treatment.

Materials and Methods

Location

A comprehensive search of PubMed and Scopus databases, along with additional searches in search engines such as Google Scholar, was done.

Data selection

The following keywords were used for the selection of studies - tumor markers AND prognosis AND salivary ADCC. Synonyms of the keywords were also used for the search. Studies published from 1977 to August 2018 were included. Only studies that were published in English were selected. Additional citations identified through the reference lists of the selected studies and bibliographic linkages were included in the review. Editorials, review, case reports, study on cell lines, articles in languages other than English were excluded from the study.

Data extraction and synthesis

A standard pilot form in excel sheet was initially used. Data extraction was done for one article and this form was reviewed by an expert and finalized. This was followed by data extraction for all the articles.

Results

The objective of the study was to evaluate the efficiency of various biomarkers in predicting the prognosis of salivary ADCC. Through the initial literature search, 326 articles were retrieved, of which 59 articles were excluded due to overlapping of data. By screening of titles, 158 articles were selected. The abstracts and full texts of these 158 articles were further screened for relevance and 58 articles were excluded. Twenty-seven case reports and reviews were ruled out. Of the remaining 73 articles, 5 articles were excluded due to data in other languages. Hence, a total of 68 articles were selected for data extraction [Figure 1]. A number of immunohistochemical markers showed prognostic significance in salivary gland ADCC. Ki-67, p53, vascular endothelial growth factor (VEGF), and cyclin D1 are the makers that were most frequently assessed, which also showed reproducible results.{Figure 1}

Study characteristics are provided in [Table 1].{Table 1}

Discussion

The combination of keywords tumor markers, prognosis, metastasis, patient survival, and salivary ADCC used for literature search in the databases showed 326 articles in the initial search, of which 68 articles fitted our criteria of immunohistochemical markers showing prognostic significance in salivary ADCC.

The primary objective of this systematic review was to identify the IHC markers, which could predict the prognosis of salivary ADCC in terms of recurrence, metastasis, and overall survival.

Many studies evaluated IHC markers such as Myb,[5] SMR3A,[6] c-MET,[7] LC3,[8] ALDH1,[9] CEACAM1,[10] PIN1,[11],[12] bcl-2,[13],[14] and HIF-1a[15] for their prognostic significance but no substantial correlation was found between the expression of these markers and prognosis. A study by Shintani et al.[16] showed that tenascin, an extracellular matrix protein, plays a role in the invasion of ADCC, but its relation with distant metastasis and recurrence was not demonstrated.

Few studies demonstrated the role of markers such as VEGF,[17] MCM3,[18] CD166,[19] LC3, and LAMP[20] as diagnostic markers for malignant tumors, thereby differentiating them from benign tumors. This highlighted their role in the progression of the tumor. However, their role as prognostic indicators was not established in these studies.

Other markers like MACC1,[21] EphA2/ephrinA1,[22] and NCAM[23] did not show any correlation with prognosis of tumor but were closely related to other clinicopathologic characteristics like perineural invasion. Similarly, Xia et al.,[24] showed decreased immunohistochemical expression of EDNRB to have a significant correlation with the growth of tumor, but no correlation was found between its expression and other characteristics like metastasis.

Dos Santos et al.[25] in a study showed that the transformed areas, in high-grade transformation of ADCC, had an increased expression of adipophilin as compared to the conventional areas, thereby suggesting the role of lipid droplets in proliferation and progression of ADCC. However, no data was available for its role in other factors of prognosis.

Further, many markers like NPM1,[26] BNIP3,[27] HIF-1a,[27] USP22,[28] FAK,[29] H3K9me3,[30] podoplanin,[31],[32] L1,[10] EN1,[33] Ezrin,[34] Cyr61,[35] EMMPRIN,[36] EZH2,[37] NF-KB,[38] iNOS,[38] galactin-3,[39] PCNA,[40] topo II,[41] MAGE-A,[42] TARP,[43] CK14,[44] CD133,[45] TACSTD2,[46] NM23[47] and LAT1[48] were shown to have a correlation with prognosis in terms of metastasis and patient survival. Since only a single study was done, it is difficult to evaluate the relevance of these markers as prognostic indicators.

Bazarsa et al.[5] showed that the low expression of Ataxia- Telangiectasia-Mutated protein, a cell cycle regulator, is related to a poor survival rate. Similar results were shown by Yi et al.[49] and Zhao et al.[50] in their studies, where reduced expression of E-cadherin and N-cadherin correlated with the metastatic progression of SACC. Decreased expression of PTEN,[29] H3K9Ac,[30] MT,[51] PDCD4,[52] beclin 1,[8] GRP78,[8],[53] Numb,[54] p27,[55] and B-catenin,[11],[12] p-Akt,[56] p-mTOR[56] and maspin[57],[58] was also related to shorter overall survival; nevertheless, not many studies were conducted for the same to predict their prognostic significance.

Few studies showed that high expression of markers like c-kit,[59],[60] EGFR,[59],[60],[61],[62] and c-erbB[40],[63] was related to unfavorable prognosis. However, other studies that evaluated the same markers did not demonstrate any correlation of these markers to prognosis. Bmi-1,[49],[64] snail,[49],[50] slug,[49],[65] ILK,[29],[50] and p63[57],[66] markers were evaluated in two studies, each of which demonstrated their significant correlation with poor prognostic factors.

Other markers such as Ki-67, p53, VEGF, and cyclin D1, were repeatedly evaluated and showed reproducible results.

Analysis of Ki-67 as a prognostic marker

The expression of cell proliferation marker, Ki-67, was evaluated in 14 studies, of which 6 studies did not show any direct correlation with the prognosis of the tumor.[18],[28],[37],[67],[68],[69] Wang et al.,[34] in 2011, showed that high expression of Ki-67 was significantly related to poor prognosis of ADCC (P < 0.037). Similar results were seen in studies conducted by Hirabayashi.[41] and Nordgård et al.[70] where statistically significant association was present between the expression of Ki-67 and short-term prognosis for patients with ACC. Kaira et al.[53] and Tang et al.[35] showed that high expression of Ki-67 was related to low 5-year overall survival rate (38.9% and 22%, respectively). Lin et al.[71] demonstrated that along with high expression of Ki-67, other factors like old age (>60), advanced tumor stage, and higher histologic grading of the tumor also contribute as predictors of poor prognosis of ADCC. Studies by Yang et al.[36] and Kaira et al.[48] demonstrated Ki-67 nuclear immunopositivity in ADCC and its higher expression in the solid histotype, and both factors were shown to have a poor prognostic effect on the overall survival.

Analysis of p53 as a prognostic marker

The role of cell cycle regulatory protein, p53, in predicting the prognosis of ADCC was evaluated in 6 studies. Out of these six studies, two studies by Kiyoshima et al.[68] and Nagler et al.[14] did not show any correlation between the expression of p53 and prognosis. A study by Bazarsad et al.[5] showed that, though a positive expression of p53 was correlated with poor survival rate, it was not statistically significant. Jia et al.,[13] in a study on prognosis of apoptosis-associated markers in ADCC, showed that the positive expression of p53 and short-term survival of patients in ADCC had a statistically significant correlation along with a solid histologic pattern. Preisegger et al.[72] studied the immunohistochemical analysis along with mutation analysis of p53 and showed that p53 could be an independent marker for poor prognosis. Similar results were shown by Kaira et al.[48] in a study, where p53 expression was significantly associated with poor prognosis.

Analysis of vascular endothelial growth factor as a prognostic marker

VEGF promotes angiogenesis, hence plays a role in tumor growth and metastasis. Three studies evaluated the prognostic significance of VEGF in ADCC Lee et al.[59] found that there was no relationship between VEGF expression and survival rate, metastasis, or recurrence in ADCC. Inconsistent with the above-mentioned study, Yang et al.[36] and Zhang et al.[38] attributed VEGF expression to be one of the factors responsible for poor prognosis along with other factors like the clinical stage, histotype, vascular invasion, perineural invasion, metastasis, and recurrence.

Cyclin D1 as a prognostic marker

Cyclin D1, a cell cycle regulator protein, was evaluated in 3 studies for its prognostic significance. All these studies produced consistent results. Schneider et al.[11] and Zhou et al.[12] in their studies investigated the prognostic significance of cyclin D1, PIN1, and β-catenin in ADCC, and no significant association was seen between the expression of cyclin D1 and patient outcome. A study by Lin et al.[71] showed similar results where the expression of cyclin D1 was not correlated with prognosis.

Conclusion

Evaluation of prognostic factors for ADCC is important as recurrence, metastasis and a short disease-free duration is a common finding after resection. The prognostic factors evaluated in our study were recurrence, metastasis, and overall survival. The study showed that many researches correlated prognosis with the overall survival and not the disease-free survival; as a result, recurrence and presence of any residual tumor could have been missed. Amongst the various prognostic markers, the histologic tissue section represents the grade of the tumor more accurately, and immunohistochemistry is the best means known to assess the tissue and its contents. Although various IHC markers have been studied to predict the prognosis of ADCC, a few markers were used repeatedly for validation of their prognostic predictability. These markers were p53, Ki-67, VEGF, and cyclin D1. However, the results obtained were not homogenous and no conclusive data could be arrived upon. Other markers that displayed an impact on outcome need additional assessment since only a single study was done. Further, comprehensive researches are therefore required in this direction to enhance the prognostic assessment.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

Bradley PJ. Adenoid cystic carcinoma of the head and neck: A review. Curr Opin Otolaryngol Head Neck Surg 2004;12:127-32.

Godge P, Sharma S, Yadav M. Adenoid cystic carcinoma of the parotid gland. Contemp Clin Dent 2012;3:223-6.

Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 2016;38:620-7.

Li Q, Huang P, Zheng C, Wang J, Ge M. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: A meta-analysis. Oncotarget 2017;8:29458-73.

Bazarsad S, Kim JY, Zhang X, Kim KY, Lee DY, Ryu MH, et al. Ataxia-telangiectasia-mutated protein expression as a prognostic marker in adenoid cystic carcinoma of the salivary glands. Yonsei Med J 2018;59:717-26.

Thierauf J, Veit JA, Grünow J, Döscher J, Weißinger S, Whiteside T, et al. Expression of submaxillary gland androgen-regulated protein 3A (SMR3A) in adenoid cystic carcinoma of the head and neck. Anticancer Res 2016;36:611-5.

Bell D, Ferrarotto R, Fox MD, Roberts D, Hanna EY, Weber RS, et al. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther 2015;16 Suppl 6:834-8.

Jiang L, Huang S, Li W, Zhang D, Zhang S, Zhang W, et al. Expression of autophagy and ER stress-related proteins in primary salivary adenoid cystic carcinoma. Pathol Res Pract 2012;208:635-41.

Zhou JH, Hanna EY, Roberts D, Weber RS, Bell D. ALDH1 immunohistochemical expression and its significance in salivary adenoid cystic carcinoma. Head Neck 2013;35:575-8.

Dahl A, Teegen J, Altevogt P, Löning T, Schumacher U. Glycoconjugate expression in adenoid cystic carcinoma of the salivary glands: Up-regulation of L1 predicts fatal prognosis. Histopathology 2011;59:299-307.

Schneider S, Thurnher D, Seemann R, Brunner M, Kadletz L, Ghanim B. The prognostic significance of b-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: B-catenin predicts overall survival. Eur Arch Otorhinolaryngol 2015;273 Suppl 5:1283-92.

Zhou CX, Gao Y. Aberrant expression of ß-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: Relation to tumor proliferation and metastasis. Oncol Rep 2006;16:505-11.

Jia L, Esguerra RL, Tang X, Yin H, Sakamoto K, Okada N, et al. Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma. Pathol Int 2004;54:217-23.

Nagler RM, Kerner H, Ben-Eliezer S, Minkov I, Ben-Itzhak O. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology 2003;64:389-98.

Costa AF, Tasso MG, Mariano FV, Soares AB, Chone CT, Crespo AN, et al. Levels and patterns of expression of hypoxia-inducible factor-1a, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation. Histopathology 2012;60 Suppl 5:816-25.

Shintani S, Alcalde RE, Matsumura T, Terakado N. Extracellular matrices expression in invasion area of adenoid cystic carcinoma of salivary glands. Cancer Lett 1997;116:9-14.

Faur AC, Lazar E, Cornianu M. Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours. APMIS 2014;122:418-26.

Ashkavandi ZJ, Najvani AD, Tadbir AA, Pardis S, Ranjbar MA, Ashraf MJ. MCM3 as a novel diagnostic marker in benign and malignant salivary gland tumors. Asian Pacific J Cancer Prev 2013;14 Suppl 6:3479-82.

Andisheh-Tadbir A, Ashraf MJ, Khademi B, Ahmadi S. Clinical implication of CD166 expression in salivary gland tumor. Tumour Biol 2015;36:2793-9.

Huang CF, Deng WW, Zhang L, Zhang WF, Sun ZJ. Expression of LC3, LAMP2, KEAP1 and NRF2 in salivary adenoid cystic carcinoma. Pathol Oncol Res 2015;22 Suppl 1:109-14.

Li H, Liao X, Liu Y, Shen Z, Gan X, Li H, et al. The expression of MACC1 and its role in the proliferation and apoptosis of salivary adenoid cystic carcinoma. J Oral Pathol Med 2015;44:810-7.

Shao Z, Zhu F, Song K, Zhang HZ, Liu K, Shang Z. EphA2/EphrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland. J Oral Maxillofac Surg 2013;71:869-78.

Shang J, Sheng L, Wang K, Shui Y, Wei Q. Expression of neural cell adhesion molecule in salivary adenoid cystic carcinoma and its correlation with perineural invasion. Oncol Rep 2007;18:1413-6.

Xia RH, Wang Z, Zhang CY, Hu YH, Zhou RR, Wang LZ, et al. Low expression of endothelial receptor B (EDNRB) is related to H3K9me3 binding with the EDNRB promoter region and is associated with the clinical T tumor stage in salivary adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;120 Suppl 2:258-68.

Dos Santos HT, Silva RN, Piña AR, de Souza do Nascimento J, de Almeida OP, Egal ES, et al. Lipid droplets are involved in the process of high-grade transformation of adenoid cystic carcinoma. Histopathology 2016;69:160-2.

Li S, Zhang X, Zhou Z, Huang Z, Liu L, Huang Z. Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. J Oral Pathol Med 2017;46:175-81.

Chen Z, Wu H, Huang S, Li W, Zhang S, Zheng P, et al. Expression of BNIP3 and its correlations to hypoxia-induced autophagy and clinicopathological features in salivary adenoid cystic carcinoma. Cancer Biomark 2015;15:467-75.

Dai W, Yao Y, Zhou Q, Sun CF. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma. PLoS One 2014;9:e87148.

Chen D, Zhang B, Kang J, Ma X, Lu Y, Gong L. Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma. Acta Otolaryngol 2013;133:203-8.

Xia R, Zhou R, Tian Z, Zhang C, Wang L, Hu Y, et al. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med 2013;137:1761-9.

Salzman R, Stárek I, Kučerová L, Skálová A. Differing Lymphatic Vessels Density in Salivary Adenoid Cystic Carcinoma and Pleomorphic Adenoma. Pathol Oncol Res 2017;23:545-50.

Wu HM, Ren GX, Wang LZ, Zhang CY, Chen WT, Guo W. Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Rep 2012;6:271-4.

Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. Cancer 2012;118:1288-92.

Wang YY, Chen WL, Huang ZQ, Yang ZH, Zhang B, Wang JG, et al. Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:96-104.

Tang QL, Fan S, Li HG, Chen WL, Shen XM, Yuan XP, et al. Expression of Cyr61 in primary salivary adenoid cystic carcinoma and its relation to Ki-67 and prognosis. Oral Oncol 2011;47:365-70.

Yang X, Dai J, Li T, Zhang P, Ma Q, Li Y, et al. Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: Correlation with tumor progression and patients' prognosis. Oral Oncol 2010;46:755-60.

Vékony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I, et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol 2008;61:744-9.

Zhang J, Peng B, Chen X. Expressions of nuclear Factor KB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: Correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005;11 Suppl 20:7334-43.

Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner JA. Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-6.

Cho KJ, Lee SS, Lee YS. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck 1999;21:414-9.

Hirabayashi S. Immunohistochemical detection of DNA topoisomerase type II alpha and Ki-67 in adenoid cystic carcinoma and pleomorphic adenoma of the salivary gland. J Oral Pathol Med 1999;28:131-6.

Beppu S, Ito Y, Fujji K, Saida K, Takino H, Masaki A, et al. Cancer-testis antigens in salivary gland cancers. Histopathology 2017;71 Suppl 2:305-15.

Yue H, Cai Y, Song Y, Meng L, Chen X, Wang M, et al. Elevated TARP promotes proliferation and metastasis of salivary adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;123:468-76.

Gao XL, Wu JS, Cao MX, Gao SY, Cen X, Jiang YP, et al. Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS One 2017;12:e0171341.

Wang SS, Gao XL, Liu X, Gao SY, Fan YL, Jiang YP, et al. CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation. Oncotarget 2016;7:29051-62.

Xia Y, Li B, Gao N, Xia H, Men Y, Liu Y, et al. Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis. Oncol Lett 2014;8:1670-4.

do Nascimento KC, de Faria PR, Dib LL, Ferreira de Aguiar MC, Cardoso SV, Chen J, et al. Immunohistochemical localization of the NM23 protein in salivary gland neoplasms with distinct biological behavior. Virchows Arch 2006;449:660-6.

Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, et al. Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol Oncol Res 2013;19:649-56.

Yi C, Li BB, Zhou CX. Bmi-1 expression predicts prognosis in salivary adenoid cystic carcinoma and correlates with epithelial-mesenchymal transition-related factors. Ann Diagn Pathol 2016;22:38-44.

Zhao D, Yang K, Tang XF, Lin NN, Liu JY. Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial-mesenchymal transition markers and tumor progression. Med Oncol 2013;30:619.

Brazão-Silva MT, Cardoso SV, de Faria PR, Dias FL, Lima RA, Eisenberg AL, et al. Adenoid cystic carcinoma of the salivary gland: A clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour. Histopathology 2013;63:802-9.

Qi C, Shao Y, Li N, Zhang C, Zhao M, Gao F. Prognostic significance of PDCD4 expression in human salivary adenoid cystic carcinoma. Med Oncol 2013;30:491.

Kaira K, Toyoda M, Shimizu A, Shino M, Sakakura K, Takayasu Y, et al. Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. Acta Otolaryngol 2016;136:1-7.

Maiorano E, Favia G, Pece S, Resta L, Maisonneuve P, Di Fiore PP, et al. Prognostic implications of NUMB immunoreactivity in salivary gland carcinomas. Int J Immunopathol Pharmacol 2007;20:779-89.

Takata T, Kudo Y, Zhao M, Ogawa I, Miyauchi M, Sato S, et al. Reduced expression of p27(Kip1) protein in relation to salivary adenoid cystic carcinoma metastasis. Cancer 1999;86:928-35.

Ouyang DQ, Liang LZ, Ke ZF, Zheng GS, Weng DS, Yang WF, et al. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma. Head Neck 2017;39:1145-54.

Taghavi N, Khozestani PK, Yazdani F, Baghban AA. Prognostic value of P63, Maspin, and MMP-2 expressionin salivary gland adenoid cystic carcinoma. Int J Cancer Manag 2018;11 Suppl 2:E7564.

Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol 2008;44:563-70.

Lee SK, Kwon MS, Lee YS, Choi SH, Kim SY, Cho KJ, et al. Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: A retrospective study. World J Surg Oncol 2012;10:266.

Bell D, Roberts D, Kies M, Rao P, Weber RS, El-Naggar AK. Cell type-dependent biomarker expression in adenoid cystic carcinoma: Biologic and therapeutic implications. Cancer 2010;116:5749-56.

Schneider T, Strehl A, Linz C, Brands R, Hartmann S, Beckford F, et al. Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. Clin Oral Investig 2016;20:541-51.

Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002;24:632-6.

Kärjä V, Syrjänen S, Kataja V, Syrjänen K. c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec 1994;56:206-12.

Chang B, Li S, He Q, Liu Z, Zhao L, Zhao T, et al. Deregulation of Bmi-1 is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma. Biochim Biophys Acta 2014;1840:3285-91.

Tang Y, Liang X, Zhu G, Zheng M, Yang J, Chen Y. Expression and importance of zinc-finger transcription factor Slug in adenoid cystic carcinoma of salivary gland. J Oral Pathol Med 2010;39:775-80.

Ramer N, Wu H, Sabo E, Ramer Y, Emanuel P, Orta L, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer 2010;116:77-83.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri A, et al. Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev 2012;13:5155-9.

Kiyoshima T, Shima K, Kobayashi I, Matsuo K, Okamura K, Komatsu S, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol 2001;37:315-22.

Norberg-Spaak L, Dardick I, Ledin T. Adenoid cystic carcinoma: Use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head Neck 2000;22:489-97.

Nordgård S, Franzén G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope 1997;107:531-6.

Lin YC, Chen KC, Lin CH, Kuo KT, Ko JY, Hong RL. Clinicopathologic features of salivary and non-salivary adenoid cystic carcinomas. Int J Oral Maxillofac Surg 2012;41:354-60.

Preisegger KH, Beham A, Kopp S, Jessernigg G, Gugl A, Stammberger H. Prognostic impact of molecular analyses in adenoid cystic carcinomas of the salivary gland. Onkologie 2001;24:273-7.

Copyright © 2024 Clinical Cancer Investigation Journal. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513